Stacy Lindborg, President and CEO of Imunon, brings nearly 30 years of biotech experience to the discussion. She shares groundbreaking insights on Imunon's IL-12 plasmid platform, which is poised to transform ovarian cancer treatment with impressive survival rates. The conversation highlights the role of AI and adaptive trial designs in drug development, and Stacy emphasizes the need for a bold, transparent company culture to drive innovation forward. Her mission-driven leadership and commitment to enhancing patient outcomes set a promising tone for the future of biotech.
17:56
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
question_answer ANECDOTE
Stacy's Pharma Career Path
Stacy Lindborg started her nearly 30-year career in pharma right after her PhD in statistics at Eli Lilly.
She gained cross-functional leadership experience early, spanning commercial, manufacturing, and R&D, focusing on innovation and drug development.
insights INSIGHT
Targeted IL-12 Delivery Insight
Immunon's IL-12 plasmid DNA platform delivers IL-12 directly into the tumor microenvironment, avoiding systemic toxicity.
This targeted approach harnesses the body’s immune response to fight ovarian cancer effectively.
question_answer ANECDOTE
Origin of Immunon's Technology
Immunon in-licensed the IL-12 plasmid technology along with Dr. Khrushchey Danwar as CSO.
Their clinical data shows long-term effect through synthetic carriers overcoming degradation challenges in gene therapy.
Get the Snipd Podcast app to discover more snips from this episode
Synopsis:
What does bold biotech leadership look like in 2025?
In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes.
Stacy shares insights from her 30-year career—from her statistical roots at Eli Lilly to her mission-driven leadership at Imunon. She highlights the groundbreaking results from Imunon’s IL-12 plasmid platform, which is showing a remarkable 13-month overall survival advantage in ovarian cancer patients and is now entering Phase 3 trials.
They also discuss the evolving biotech landscape, how adaptive trial designs and AI are unlocking clinical potential, and why cultivating a bold, transparent company culture is key to advancing transformational science.
Biography:
Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon’s Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company’s Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.
Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&D strategy.
Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.
Biotech 2050 Podcast